Evidence map›Paper›PMID 39494100›Full record

ArticleWorld journal of gastroenterology2024

Tofacitinib for ulcerative colitis: A promising treatment option.

Zong-Qiang Han, Li-Na Wen

Abstract readLetter
In one paragraph

Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zong-Qiang HanDepartment of Laboratory Medicine, Beijing Xiaotangshan Hospital, Beijing 102211, China.
Li-Na WenDepartment of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China. wenlina3074@bjsjth.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A single center retrospective clinical study revealed the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC). This study has clinical reference value but also has some limitations. Previous studies, including this clinical trial, have shown that tofacitinib could be a promising treatment option for UC, but further clinical research is required to prove this point.

Indexed as

Colitis, UlcerativePiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinibClinical trialsEfficacySafetyTofacitinibUlcerative colitis

Identifiers

PMID39494100
PMCPMC11525864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.